Abstract
Mitochondrial dynamics play a crucial role in the pathobiology underlying Alzheimers disease (AD) and Parkinsons disease (PD). Although a complete scientific understanding of these devastating conditions has yet to be realized, alterations in mitochondrial fission and fusion, and in the protein complexes that orchestrate mitochondrial fission and fusion, have been well established in AD- and PD-related neurodegeneration. Whether fission/fusion disruption in the brain is a causal agent in neuronal demise or a product of some other upstream disturbance is still a matter of debate; however, in both AD and PD, the potential for successful therapeutic amelioration of degeneration via mitochondrial protection is high. We here discuss the role of mitochondrial dynamics in AD and PD and assess the need for their therapeutic exploitation.
Keywords: Alzheimer's disease, DLP-1, Drp-1, Fis1, fission, fusion, Mfn1, Mfn2, mitochondrial dynamics, neurodegeneration, Parkinson's disease, therapeutics
Current Pharmaceutical Design
Title: The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention
Volume: 17 Issue: 31
Author(s): David J. Bonda, Mark A. Smith, George Perry, Hyoung-gon Lee, Xinglong Wang and Xiongwei Zhu
Affiliation:
Keywords: Alzheimer's disease, DLP-1, Drp-1, Fis1, fission, fusion, Mfn1, Mfn2, mitochondrial dynamics, neurodegeneration, Parkinson's disease, therapeutics
Abstract: Mitochondrial dynamics play a crucial role in the pathobiology underlying Alzheimers disease (AD) and Parkinsons disease (PD). Although a complete scientific understanding of these devastating conditions has yet to be realized, alterations in mitochondrial fission and fusion, and in the protein complexes that orchestrate mitochondrial fission and fusion, have been well established in AD- and PD-related neurodegeneration. Whether fission/fusion disruption in the brain is a causal agent in neuronal demise or a product of some other upstream disturbance is still a matter of debate; however, in both AD and PD, the potential for successful therapeutic amelioration of degeneration via mitochondrial protection is high. We here discuss the role of mitochondrial dynamics in AD and PD and assess the need for their therapeutic exploitation.
Export Options
About this article
Cite this article as:
J. Bonda David, A. Smith Mark, Perry George, Lee Hyoung-gon, Wang Xinglong and Zhu Xiongwei, The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072562
DOI https://dx.doi.org/10.2174/138161211798072562 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Central Nervous System Agents in Medicinal Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches
CNS & Neurological Disorders - Drug Targets Garlic and its Active Compounds: A Potential Candidate in The Prevention of Cancer by Modulating Various Cell Signalling Pathways
Anti-Cancer Agents in Medicinal Chemistry Effect of Phosphorylation and Aggregation on Tau Binding to Dna
Protein & Peptide Letters Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease
Protein & Peptide Letters Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry